BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kobayashi T, Ito K, Kojima T, Kato M, Kanda S, Hatakeyama S, Matsui Y, Matsushita Y, Naito S, Shiga M, Miyake M, Muro Y, Nakanishi S, Kato Y, Shibuya T, Hayashi T, Yasumoto H, Yoshida T, Uemura M, Taoka R, Kamiyama M, Ogawa O, Kitamura H, Nishiyama H; Japan Urological Oncology Group. Risk stratification for the prognosis of patients with chemoresistant urothelial cancer treated with pembrolizumab. Cancer Sci 2021;112:760-73. [PMID: 33283385 DOI: 10.1111/cas.14762] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 10.3] [Reference Citation Analysis]
Number Citing Articles
1 Nakamori K, Yamazaki S, Komura K, Fukuokaya W, Adachi T, Hirasawa Y, Hashimoto T, Yoshizawa A, Ohno T, Yano Y, Nishimura K, Tokushige S, Uchimoto T, Yamamoto S, Iwatani K, Urabe F, Mori K, Yanagisawa T, Tsuduki S, Takahara K, Inamoto T, Miki J, Kimura T, Ohno Y, Shiroki R, Azuma H. Concurrent palliative radiation with pembrolizumab for platinum-refractory urothelial carcinoma is associated with improved overall survival. Clin Transl Radiat Oncol 2023;39:100558. [PMID: 36545361 DOI: 10.1016/j.ctro.2022.12.001] [Reference Citation Analysis]
2 Ito K, Kita Y, Kobayashi T. Real‐world outcomes of pembrolizumab for platinum‐refractory advanced urothelial carcinoma: Efficacy, safety, and evidence for trial‐unfit patients. Int J of Urology 2022. [DOI: 10.1111/iju.15101] [Reference Citation Analysis]
3 Hamada A, Sano T, Kita Y, Takada H, Sakatani T, Nakamura K, Ito K, Goto T, Sawada A, Akamatsu S, Kobayashi T. Limited predictive impact of tumor size dynamics on further tumor shrinkage after 4 cycles of first-line chemotherapy in patients with advanced urothelial carcinoma. Urol Oncol 2022;40:540.e1-540.e10. [PMID: 36008256 DOI: 10.1016/j.urolonc.2022.07.008] [Reference Citation Analysis]
4 Yoshida T, Ohe C, Ito K, Takada H, Saito R, Kita Y, Sano T, Tsuta K, Kinoshita H, Kitamura H, Nishiyama H, Kobayashi T, On behalf of the Japan Urological Oncology Group. Clinical and molecular correlates of response to immune checkpoint blockade in urothelial carcinoma with liver metastasis. Cancer Immunol Immunother 2022;71:2815-2828. [DOI: 10.1007/s00262-022-03204-6] [Reference Citation Analysis]
5 Iida K, Naiki T, Etani T, Nagai T, Sugiyama Y, Isobe T, Aoki M, Nozaki S, Noda Y, Shimizu N, Tomiyama N, Gonda M, Kamiya H, Kubota H, Nakane A, Ando R, Kawai N, Yasui T. Proton pump inhibitors/potassium-competitive acid blockers decrease pembrolizumab efficacy in patients with metastatic urothelial carcinoma.. [DOI: 10.21203/rs.3.rs-2158631/v1] [Reference Citation Analysis]
6 Lin CT, Su PJ, Huang SY, Wu CC, Wang HJ, Cheng YT, Luo HL, Chen CH, Liu TT, Huang CC, Su YL. First-line Immune Checkpoint Inhibitor Versus Immune Checkpoint Inhibitor With Chemotherapy for Cisplatin-ineligible Metastatic Urothelial Carcinoma: Evidence From a Real-world, Multicenter Analysis. J Immunother 2022. [PMID: 36121316 DOI: 10.1097/CJI.0000000000000441] [Reference Citation Analysis]
7 Fukuokaya W, Yanagisawa T, Hashimoto M, Yamamoto S, Koike Y, Imai Y, Iwatani K, Onuma H, Ito K, Urabe F, Tsuzuki S, Kimura S, Miki J, Oyama Y, Abe H, Kimura T. Effectiveness of pembrolizumab in trial-ineligible patients with metastatic urothelial carcinoma. Cancer Immunol Immunother 2022. [DOI: 10.1007/s00262-022-03291-5] [Reference Citation Analysis]
8 Kita Y, Ito K, Kanda S, Joraku A, Yamaguchi R, Shimizu Y, Hayata N, Somiya S, Shibasaki N, Kimura T, Hikami K, Yamada T, Abe T, Tsuchihashi K, Tatarano S, Nishiyama H, Kitamura H, Kobayashi T. Tolerability and treatment outcome of pembrolizumab in patients with advanced urothelial carcinoma and severe renal dysfunction. Urologic Oncology: Seminars and Original Investigations 2022;40:410.e11-410.e18. [DOI: 10.1016/j.urolonc.2022.04.005] [Reference Citation Analysis]
9 Taguchi S, Kawai T, Nakagawa T, Miyakawa J, Kishitani K, Sugimoto K, Nakamura Y, Kamei J, Obinata D, Yamaguchi K, Kaneko T, Yoshida K, Yamamoto S, Kakutani S, Kanazawa K, Sugihara Y, Tokunaga M, Matsumoto A, Uemura Y, Akiyama Y, Yamada Y, Sato Y, Yamada D, Enomoto Y, Nishimatsu H, Ishikawa A, Tanaka Y, Nagase Y, Fujimura T, Fukuhara H, Takahashi S, Kume H. Improved survival in real-world patients with advanced urothelial carcinoma: A multicenter propensity score-matched cohort study comparing a period before the introduction of pembrolizumab (2003-2011) and a more recent period (2016-2020). Int J Urol 2022. [PMID: 35996761 DOI: 10.1111/iju.15014] [Reference Citation Analysis]
10 Ito K, Kita Y, Yokomizo A, Miki J, Yoshio Y, Matsumoto H, Segawa T, Karashima T, Nishiyama N, Imai K, Suekane S, Nagasawa S, Higashi S, Nishiyama H, Kitamura H, Kobayashi T. Discontinuation of pembrolizumab for advanced urothelial carcinoma without disease progression: Nationwide cohort study. Cancer Med 2022. [PMID: 35864744 DOI: 10.1002/cam4.5057] [Reference Citation Analysis]
11 Shindo T, Maehana T, Tanaka T, Hashimoto K, Kobayashi K, Takahashi A, Hotta H, Kunishima Y, Taguchi K, Tachiki H, Ito N, Matsukawa M, Kato R, Miyamoto S, Hinotsu S, Masumori N. Are there differences in the characteristics of patients who respond to gemcitabine plus cisplatin chemotherapy and those who respond to pembrolizumab therapy for metastatic urothelial carcinoma? Multicenter retrospective study. Int J Urol 2022. [PMID: 35654444 DOI: 10.1111/iju.14941] [Reference Citation Analysis]
12 Russell BM, Boussi L, Bellmunt J. Management of Advanced Urothelial Carcinoma in Older and Frail Patients: Have Novel Treatment Approaches Improved Their Care? Drugs Aging 2022;39:271-84. [PMID: 35344197 DOI: 10.1007/s40266-022-00933-2] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Togashi K, Hatakeyama S, Yoneyama T, Hamaya T, Narita T, Fujita N, Iwamura H, Okamoto T, Yamamoto H, Yoneyama T, Hashimoto Y, Ohyama C. Effect of active anticancer therapy on serologic response to SARS-CoV-2 BNT162b2 vaccine in patients with urothelial and renal cell carcinoma. Int J Urol 2022. [PMID: 35362143 DOI: 10.1111/iju.14882] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
14 Shimizu T, Miyake M, Nishimura N, Inoue K, Fujii K, Iemura Y, Ichikawa K, Omori C, Tomizawa M, Maesaka F, Oda Y, Miyamoto T, Sakamoto K, Kiba K, Tanaka M, Oyama N, Okajima E, Fujimoto K, Hori S, Morizawa Y, Gotoh D, Nakai Y, Torimoto K, Tanaka N, Fujimoto K. Organ-Specific and Mixed Responses to Pembrolizumab in Patients with Unresectable or Metastatic Urothelial Carcinoma: A Multicenter Retrospective Study. Cancers (Basel) 2022;14:1735. [PMID: 35406508 DOI: 10.3390/cancers14071735] [Reference Citation Analysis]
15 Kita Y, Ito K, Sano T, Hashimoto K, Mochizuki T, Shiraishi Y, Araki H, Fujiwara M, Kanamaru S, Takahashi T, Hishiki K, Okada T, Ogawa K, Ito M, Kojima T, Nishiyama N, Matsui Y, Nishiyama H, Kitamura H, Kobayashi T. Clinical practice pattern in patients with advanced urothelial cancer who had progressed on pembrolizumab in the pre-enfortumab vedotin era. Int J Urol 2022. [PMID: 35304776 DOI: 10.1111/iju.14861] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Lai HY, Chiu CC, Kuo YH, Tsai HH, Wu LC, Tseng WH, Liu CL, Hsing CH, Huang SK, Li CF. High Stromal SFRP2 Expression in Urothelial Carcinoma Confers an Unfavorable Prognosis. Front Oncol 2022;12:834249. [PMID: 35372028 DOI: 10.3389/fonc.2022.834249] [Reference Citation Analysis]
17 Nishimura K, Nishio K, Hirosuna K, Komura K, Hayashi T, Fukuokaya W, Ura A, Uchimoto T, Nakamura K, Fukushima T, Yano Y, Takahashi N, Nakamori K, Kinoshita S, Matsunaga T, Tsutsumi T, Tsujino T, Taniguchi K, Tanaka T, Uehara H, Takahara K, Inamoto T, Hirose Y, Kimura T, Egawa S, Azuma H. Efficacy of pembrolizumab and comprehensive CD274/PD-L1 profiles in patients previously treated with chemoradiation therapy as radical treatment in bladder cancer. J Immunother Cancer 2022;10:e003868. [PMID: 35039462 DOI: 10.1136/jitc-2021-003868] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Sakatani T, Kita Y, Fujimoto M, Sano T, Hamada A, Nakamura K, Takada H, Goto T, Sawada A, Akamatsu S, Kobayashi T. IFN-Gamma Expression in the Tumor Microenvironment and CD8-Positive Tumor-Infiltrating Lymphocytes as Prognostic Markers in Urothelial Cancer Patients Receiving Pembrolizumab. Cancers (Basel) 2022;14:263. [PMID: 35053427 DOI: 10.3390/cancers14020263] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
19 Hatakeyama S, Narita S, Okita K, Narita T, Iwamura H, Fujita N, Inokuchi J, Matsui Y, Kitamura H, Ohyama C. Management of bladder cancer in older patients. Jpn J Clin Oncol 2021:hyab187. [PMID: 34905776 DOI: 10.1093/jjco/hyab187] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
20 Yanagisawa T, Mori K, Katayama S, Mostafaei H, Quhal F, Laukhtina E, Rajwa P, Motlagh RS, Aydh A, König F, Grossmann NC, Pradere B, Miki J, Kimura T, Egawa S, Shariat SF. Pretreatment clinical and hematologic prognostic factors of metastatic urothelial carcinoma treated with pembrolizumab: a systematic review and meta-analysis. Int J Clin Oncol 2021. [PMID: 34757531 DOI: 10.1007/s10147-021-02061-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Kawashima A, Yamamoto Y, Sato M, Nakata W, Kakuta Y, Ishizuya Y, Yamaguchi Y, Yamamoto A, Yoshida T, Takayama H, Takada T, Inoue H, Okuda Y, Kato T, Hatano K, Uemura M, Nonomura N, Imamura R. FAN score comprising fibrosis-4 index, albumin-bilirubin score and neutrophil-lymphocyte ratio is a prognostic marker of urothelial carcinoma patients treated with pembrolizumab. Sci Rep 2021;11:21199. [PMID: 34707147 DOI: 10.1038/s41598-021-00509-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
22 Okuyama Y, Hatakeyama S, Numakura K, Narita T, Tanaka T, Miura Y, Sasaki D, Noro D, Tokui N, Okamoto T, Yamamoto H, Narita S, Yoneyama T, Hashimoto Y, Habuchi T, Ohyama C. Prognostic impact of proton pump inhibitors for immunotherapy in advanced urothelial carcinoma. BJUI Compass 2022;3:154-61. [DOI: 10.1002/bco2.118] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
23 Kato M, Kobayashi T, Matsui Y, Ito K, Hikami K, Yamada T, Ogawa K, Nakamura K, Sassa N, Yokomizo A, Abe T, Tsuchihashi K, Tatarano S, Inokuchi J, Tomida R, Fujiwara M, Takahashi A, Matsumoto K, Shimizu K, Araki H, Kurahashi R, Ozaki Y, Tashiro Y, Uegaki M, Kojima T, Uchida J, Ogawa O, Nishiyama H, Kitamura H; Japan Urological Oncology Group. Impact of the objective response to and number of cycles of platinum-based first-line chemotherapy for metastatic urothelial carcinoma on overall survival of patients treated with pembrolizumab. Int J Urol 2021;28:1261-7. [PMID: 34545627 DOI: 10.1111/iju.14686] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
24 Taoka R, Kobayashi T, Hidaka Y, Abe H, Ito K, Kojima T, Kato M, Kanda S, Hatakeyama S, Matsui Y, Matsushita Y, Naito S, Shiga M, Miyake M, Muro Y, Nakanishi S, Kato Y, Shibuya T, Hayashi T, Yasumoto H, Yoshida T, Uemura M, Kamiyama M, Morita S, Ogawa O, Nishiyama H, Kitamura H, Sugimoto M; Japan Urological Oncology Group. Impact of prior intravesical bacillus Calmette-Guerin therapy on the effectiveness of pembrolizumab for patients with metastatic urothelial carcinoma. Urol Oncol 2021:S1078-1439(21)00361-6. [PMID: 34454824 DOI: 10.1016/j.urolonc.2021.08.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
25 Hamada A, Sano T, Matsumoto K, Sakatani T, Nakamura K, Sawada A, Akamatsu S, Matsui Y, Ogawa O, Kobayashi T. Modification of Platinum-based Systemic Chemotherapy for Advanced Urothelial Carcinoma in Patients With Suboptimal Renal Function. In Vivo 2021;35:2821-9. [PMID: 34410974 DOI: 10.21873/invivo.12569] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
26 Kobayashi T, Takeuchi A, Nishiyama H, Eto M. Current status and future perspectives of immunotherapy against urothelial and kidney cancer. Jpn J Clin Oncol 2021:hyab121. [PMID: 34389866 DOI: 10.1093/jjco/hyab121] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
27 Ishiyama Y, Kondo T, Nemoto Y, Kobari Y, Ishihara H, Tachibana H, Yoshida K, Hashimoto Y, Takagi T, Iizuka J, Tanabe K. Antibiotic use and survival of patients receiving pembrolizumab for chemotherapy-resistant metastatic urothelial carcinoma. Urol Oncol 2021;39:834.e21-8. [PMID: 34284929 DOI: 10.1016/j.urolonc.2021.05.033] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
28 Uchimoto T, Komura K, Fukuokaya W, Kimura T, Takahashi K, Yano Y, Nishimura K, Nakamori K, Fujiwara Y, Matsunaga T, Tsutsumi T, Tsujino T, Maenosono R, Yoshikawa Y, Taniguchi K, Tanaka T, Uehara H, Hirano H, Nomi H, Takahara K, Inamoto T, Egawa S, Azuma H. Risk Classification for Overall Survival by the Neutrophil-Lymphocyte Ratio and the Number of Metastatic Sites in Patients Treated with Pembrolizumab-A Multicenter Collaborative Study in Japan. Cancers (Basel) 2021;13:3554. [PMID: 34298768 DOI: 10.3390/cancers13143554] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
29 Kobayashi T, Ito K, Kojima T, Maruyama S, Mukai S, Tsutsumi M, Miki J, Okuno T, Yoshio Y, Matsumoto H, Shimazui T, Segawa T, Karashima T, Masui K, Fukuta F, Tashiro K, Imai K, Suekane S, Nagasawa S, Higashi S, Fukui T, Ogawa O, Kitamura H, Nishiyama H. Pre-pembrolizumab neutrophil-to-lymphocyte ratio (NLR) predicts the efficacy of second-line pembrolizumab treatment in urothelial cancer regardless of the pre-chemo NLR. Cancer Immunol Immunother 2021. [PMID: 34235546 DOI: 10.1007/s00262-021-03000-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
30 Nishiyama N, Kobayashi T, Narita S, Hidaka Y, Ito K, Maruyama S, Mukai S, Tsutsumi M, Miki J, Okuno T, Yoshio Y, Matsumoto H, Shimazui T, Segawa T, Karashima T, Masui K, Fukuta F, Tashiro K, Imai K, Suekane S, Nagasawa S, Higashi S, Fukui T, Kojima T, Morita S, Ogawa O, Nishiyama H, Kitamura H; Japan Urological Oncology Group. Efficacy and safety of pembrolizumab for older patients with chemoresistant urothelial carcinoma assessed using propensity score matching. J Geriatr Oncol 2021:S1879-4068(21)00164-8. [PMID: 34238726 DOI: 10.1016/j.jgo.2021.07.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
31 Tural D, Ölmez ÖF, Sümbül AT, Özhan N, Çakar B, Köstek O, Ekenel M, Erman M, Coşkun HŞ, Selçukbiricik F, Keskin Ö, Türköz FP, Oruç K, Bayram S, Bilgetekin İ, Yıldız B, Şendur MAN, Paksoy N, Dirican A, Erdem D, Selam M, Tanrıverdi Ö, Paydaş S, Urakçı Z, Atağ E, Güncan S, Ürün Y, Alkan A, Kaya AO, Özyükseler DT, Taşkaynatan H, Yıldırım M, Sönmez M, Başoğlu T, Gündüz Ş, Kılıçkap S, Artaç M. Prognostic factors in patients with metastatic urothelial carcinoma who have treated with Atezolizumab. Int J Clin Oncol 2021;26:1506-13. [PMID: 34023933 DOI: 10.1007/s10147-021-01936-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
32 Fornarini G, Rebuzzi SE, Banna GL, Calabrò F, Scandurra G, De Giorgi U, Masini C, Baldessari C, Naglieri E, Caserta C, Manacorda S, Maruzzo M, Milella M, Buttigliero C, Tambaro R, Ermacora P, Morelli F, Nolè F, Astolfi C, Sternberg CN. Immune-inflammatory biomarkers as prognostic factors for immunotherapy in pretreated advanced urinary tract cancer patients: an analysis of the Italian SAUL cohort. ESMO Open 2021;6:100118. [PMID: 33984678 DOI: 10.1016/j.esmoop.2021.100118] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
33 Ito K, Kobayashi T, Kojima T, Hikami K, Yamada T, Ogawa K, Nakamura K, Sassa N, Yokomizo A, Abe T, Tsuchihashi K, Tatarano S, Inokuchi J, Tomida R, Fujiwara M, Takahashi A, Matsumoto K, Shimizu K, Araki H, Kurahashi R, Osaki Y, Tashiro Y, Uegaki M, Ogawa O, Kitamura H, Nishiyama H. Pembrolizumab for treating advanced urothelial carcinoma in patients with impaired performance status: Analysis of a Japanese nationwide cohort. Cancer Med 2021;10:3188-96. [PMID: 33931987 DOI: 10.1002/cam4.3863] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
34 Okita K, Hatakeyama S, Hagiwara K, Suzuki Y, Tanaka T, Noro D, Tokui N, Fujita N, Konishi S, Okamoto T, Yoneyama T, Yamamoto H, Yoneyama T, Hashimoto Y, Ohyama C. The effect of number of treatment cycles of platinum-based first-line chemotherapy on maximum radiological response in patients with advanced urothelial carcinoma. Urol Oncol 2021;39:832.e17-23. [PMID: 33865689 DOI: 10.1016/j.urolonc.2021.03.011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
35 Kobayashi T, Ito K, Kojima T, Kato M, Kanda S, Hatakeyama S, Matsui Y, Matsushita Y, Naito S, Shiga M, Miyake M, Muro Y, Nakanishi S, Kato Y, Shibuya T, Hayashi T, Yasumoto H, Yoshida T, Uemura M, Taoka R, Kamiyama M, Ogawa O, Kitamura H, Nishiyama H; Japan Urological Oncology Group. Risk stratification for the prognosis of patients with chemoresistant urothelial cancer treated with pembrolizumab. Cancer Sci 2021;112:760-73. [PMID: 33283385 DOI: 10.1111/cas.14762] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 10.3] [Reference Citation Analysis]